The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol.
The pharmacokinetics of diacetyldianhydrogalactitol (DADAG) was compared in mice, rats, and humans. The ratios of human therapeutic dose (ThD) to the LD10 were 8 and 5 in mice and rats, respectively. The ratios of the corresponding AUCs of DADAG were 20 and 17, whereas those of dianhydrogalactitol (DAG), the main, active metabolite of DADAG, were 8 in both species. The lower human-to-rodent ratio for DAG was due to the fact that twice as much DAG was formed in the animals. Other factors contributing to the larger AUC in man were the 3-5 times smaller distribution volume found in humans as well as the lower hexitol sensitivity of human bone marrow cells. We conclude that in addition to the distance between the AUCs of the LD10 and of the human starting dose, interspecies pharmacokinetic differences should also be considered in planning the rate of dose escalation.
Kerpel-Fronius
S
S
National Institute of Oncology, Budapest, Hungary.
Erdélyi-Tóth
V
V
Somfai-Relle
S
S
Csetényi
J
J
Kovács
P
P
Ujj
G
G
Kanyár
B
B
D000465:Algorithms; D000818:Animals; D003961:Dianhydrogalactitol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008808:Mice, Inbred CBA; D051381:Rats; D011919:Rats, Inbred Strains; D013402:Sugar Alcohols / Q000493:pharmacokinetics*
D013402:Sugar Alcohols; D003961:Dianhydrogalactitol; C027991:dianhydro-3,4-diacetylgalactitol